Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Axovant tips nelotanserin from small molecule R&D Axovant has stopped nelotanserin development after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia. The d...
Burn is a global public health problem, causing more than 180,000 deaths per year acros...
A Burn takes place when the skin comes into contact with a heat source. Burns can occur...
Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...
The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...
The organ on a chip is a microfluidic culture device that recapitulates the complicated...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
-Agonist.png "Toll-like Receptors Agonist")
